Upadacitinib Effective Long Term for AD in Adolescents

An analysis of three phase 3 trials reported relief with upadacitinib through 76 weeks in adolescents with AD.
Medscape Medical News

source https://www.medscape.com/viewarticle/upadacitinib-effective-long-term-ad-adolescents-2024a1000jmf?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost